AG
LJPC

Aperio Group’s La Jolla Pharmaceutical Company LJPC Stock Holding History

Aperio Group’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-1,726
Closed -$16K – 3078
2019
Q2 		$16K Buy
+1,726
New +$13K ﹤0.01% 2725

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Aperio Group's LJPC Position: Q3 2019 in Review

Aperio Group sold out of La Jolla Pharmaceutical Company (LJPC) in Q3 2019, closing a stake of 1,726 shares — an estimated $16K sold.

Aperio Group first reported a position in LJPC in Q2 2019 and held it in 1 quarter. The position peaked at $16K in Q2 2019. 75 funds tracked by Wall St. Rank hold LJPC as of Q3 2019.

  • Aperio Group reported no remaining La Jolla Pharmaceutical Company position as of Q3 2019 after selling out during the quarter.
  • Aperio Group sold 1,726 La Jolla Pharmaceutical Company shares in Q3 2019, an estimated $16K.
  • Aperio Group first reported a position in La Jolla Pharmaceutical Company in Q2 2019 and held it in 1 quarter.
  • Aperio Group's La Jolla Pharmaceutical Company position peaked at $16K in Q2 2019.
  • 75 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2019.

Based on Aperio Group's 13F filing for Q3 2019, filed 6 Nov 2019.